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Bacterial strains, plasmids, materials, and instrum entation: Chemically compe-
tent E. coli TOP10 and BL21 (DE3) were bought from Invitrogen. Restriction endo-
nucleases, T4 DNA ligase, and Phusion DNA polymerase were purchased from NEB. 
DNA primers for PCR were purchased from Integrated DNA Technologies. The 
pET28a and pET22b vectors were purchased from Novagen. The Int-pET19b-pps 
containing a decahistidine tag separated from the gene by PreScission protease was 
generously provided by Dr. Tapan Biswas (Univeristy of Michigan, MI, USA).[1] Preci-
sion protease was purchased from GE Healthcare (Piscataway, NJ, USA). DNA se-
quencing was performed at the University of Michigan DNA sequencing Core. DTDP, 
commercially available CoA derivatives (acetoacetyl-CoA, acetyl-CoA, benzoyl-CoA, 
butyryl-CoA, crotonyl-CoA, glutaryl-CoA, D,L-β-hydroxybutyryl-CoA, isovaleryl-CoA, 
malonyl-CoA, methylmalonyl-CoA, palmitoyl-CoA, n-propionyl-CoA,) and aminoglyco-
sides (amikacin, gentamicin, kanamycin A, neomycin B, paromomycin, sisomicin, and 
tobramycin) were purchased from Sigma-Aldrich and used without any further purifi-
cation. ThioGlo-1 (TG1) was bought from Calbiochem. Determination of kinetic par-
ameters by UV-Vis assays was done on a multimode SpectraMax M5 plate reader by 
using 96-well plates (Fisher Scientific). Fast protein liquid chromatography (FPLC) 
was performed as the last protein purification step on a Bio-Rad BioLogic DuoFlow 
using a HighPrepTM 26/60 SephacrylTM S-200 High Resolution column. 
Methods: 
Preparation of pAAC(6’)-APH(2”)-pET28a, pAAC(6’)-AP H(2”)-pET22b, pAAC(6’)-
APH(2”)-Int-pET19b-pps, pAAC(3)-IV-pET28a, and pAAC (3)-IV-Int-pET19b-pps 
Overexpression Constructs. The gene encoding AAC(6’)-APH(2”) was PCR-ampli-
fied using the vector pSF815 in which the gene was stored as a template (provided 
by Prof. Timor Baasov, Israel Institute of Technology) and Phusion High-Fidelity DNA 
polymerase. The gene encoding AAC(3)-IV was PCR-amplified using plasmid DNA 
pAAC(3)-IV-pET23a (a gift from Dr. John S. Blanchard, Albert Einstein College of 
Medicine, NY). The primers used for the amplification of each gene are listed in Table 
S1. The amplified genes were inserted into the linearized pET28a, pET22b, and Int-
pET19b-pps vectors via the corresponding NdeI/XhoI (pAAC(6’)-APH(2”)-pET28a-
(NHis), pAAC(6’)-APH(2”)-pET22b(CHis), and pAAC(6’)-APH(2”)-Int-pET19b-pps-
(NHis)), NdeI/HindIII (pAAC(3)-IV-pET28a(NHis)), and NdeI/BamHI (pAAC(3)-IV-Int-
pET19b-pps(NHis)) restriction sites, to afford constructs that encode for NHis-tagged 
and CHis-tagged proteins. The Int-pET19b-pps vector was utilized to produce pro-
teins with an easily cleavable NHis-tag by use of precision protease. Expression of 
AAC(6’)-APH(2”)-pET28a(NHis), AAC(6’)-APH(2”)-pET22b(CHis), AAC(6’)-APH(2”)-
Int-pET19b-pps(NHis), AAC(3)-IV-pET28a(NHis), and AAC(3)-IV-Int-pET19b-pps-
(NHis) was done following transformation into E. coli TOP10 competent cells. The 
plasmids were sequenced (The University of Michigan DNA Sequencing Core) and 
showed perfect alignment with the reported sequences (PubMed accession number 





Overproduction and Purification of AAC(6’)-APH(2”)( NHis), AAC(6’)-APH(2”)-
(CHis), and AAC(3)-IV(NHis). Purified plasmids AAC(6’)-APH(2”)-pET28a(NHis), 
AAC(6’)-APH(2”)-pET22b(CHis), AAC(6’)-APH(2”)-Int-pET19b-pps(NHis), AAC(3)-IV-
pET28a(NHis), and AAC(3)-IV-Int-pET19b-pps(NHis) were transformed into E. coli 
BL21 (DE3) competent cells for protein expression and purification. 1 L of Luria-Ber-
tani (LB) medium supplemented with kanamycin (50 µg/mL) (for pET28a constructs) 
or ampicillin (100 µg/mL) (for pET22b and Int-pET19b-pps constructs) were inoculat-
ed with 10 mL of an overnight culture of the transformants harboring the AAC(6’)-
APH(2”)-pET28a, AAC(6’)-APH(2”)-pET22b, AAC(6’)-APH(2”)-Int-pET19b-pps, 
AAC(3)-IV-pET28a, and AAC(3)-IV-Int-pET19b-pps constructs and incubated at 37 
°C. The cultures were grown to an OD600 of ~0.6, induced with 1 mL of a 1 M stock of 
isopropryl-β-thiogalactopyranoside (IPTG) (final concentration of 1.0 mM) and shaken 
for an additional 4 h at 37 °C. Cells were harvested by centrifugation (6000 rpm, 10 
min, 4 °C, Beckman Coulter Aventi JE centrifuge, F10 rotor) and resuspended in 
buffer A [300 mM NaCl and 50 mM Na2HPO4 pH 8.0 adjusted at RT, (containing 10% 
Table S1.  Primers used for the PCR amplification of the AAC(6’)-APH(2”) gene from S. 
aureus and the AAC(3)-IV gene from E. coli.  
gene (vector used for 
cloning) 

























The introduced restriction sites are underlined for each primer. The 5’ primers all introduced an NdeI restric-
tion site. The 3’ primer for aac(3)-IV(NHis) (pET28a), aac(3)-IV(NHis) (Int-pET19b-pps), and all aac(6’)-
aph(2”) introduced HindIII, BamHI, and XhoI restriction sites, respectively. 
The tags added to the proteins are: 
NHis (pET28a/NdeI) = MGSSHHHHHHSSGLVPRGSH 
NHis (Int-pET19b-pps/NdeI) = MGHHHHHHHHHHSSGHINNNNKHTSLEVLFQGPH 
No tag (after cleavage using precision protease and Int-pET19b-pps/NdeI) = GPH 
CHis (pET22b/XhoI) = LEHHHHHH 
CHis (pET22b/HindIII) = KLAALEHHHHHH 
glycerol for the AAC(3)-IV proteins)]. Resuspended cells were lysed (1 pass at 
10 000-15 000 psi, Avestin EmulsiFlex-C3 high-pressure homogenizer), and the cell 
debris was removed by centrifugation (16 000 rpm, 45 min, 4 °C, Beckman Beckman 
Coulter Aventi JE centrifuge, JA-17 rotor). Imidazole (final concentration of 2 mM) 
was added to the supernatant, which was then incubated with 2 mL of Ni-NTA aga-
rose resin (Qiagen) at 4 °C for 2 h with gentle rocking. The resin was loaded onto a 
column and washed with 10 mL of buffer A containing 5 mM imidazole and with 10 
mL of buffer A containing 20 mM imidazole. The desired protein was eluted from the 
column in a stepwise imidazole gradient (10 mL fraction of 20 mM (1x), 5 mL frac-
tions of 20 mM (3x), 40 mM (3x), and 250 mM imidazole (3x)). Fractions containing the 
pure desired proteins [as determined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE)] were combined and dialyzed at 4 °C against 1 L of 
buffer B [50 mM HEPES, pH 7.5 adjusted at RT] for 3 h. The dialyzed proteins were 
either further purified on FPLC (1.5 mL/min using buffer C [50 mM HEPES, pH 7.5 
adjusted at RT]) or treated with precision protease to cleave the NHis tag from the 
proteins produced using the Int-pET19b-pps vector (see protocol in the next section) 
(Figures S1, S3, and S4). Pure proteins were concentrated using Amicon Ultra PL-10. 
Protein concentrations were determined using a Nanodrop spectrometer (Thermo 
Scientific). Protein yields were 1.3-5.1 mg per L of culture for all AAC(6’)-APH(2”) and 
3-22 mg per L of culture of all AAC(3)-IV. All AAC(6’)-APH(2”) proteins were stored at 
4 °C while all AAC(3)-IV proteins were flash-frozen (with 10% glycerol added to the 
protein) using liquid nitrogen and stored at -80 °C. 
Cleavage of NHis Tag from AAC(6’)-APH(2”) Produced from the Int-pET19b-pps 
Construct. The NHis tag was cleaved overnight at 4 °C with rocking using 30 µg of 
PreScission protease in 50 mM HEPES (pH 7.5 adjusted at RT). The protein was 
loaded on 15% SDS-PAGE gel to verify that the tag was completely removed. If 
cleavage was incomplete, an additional 30 µg of precision protease was added and 
rocked at RT for an additional 3-6 h. The cleavage progress was checked again by 
SDS-PAGE gel and if incomplete, the remaining tagged protein was separated from 
the untagged by binding to Ni-NTA agarose beads. The flow-through was collected 
and purified by FPLC (1.5 mL/min using buffer C [50 mM HEPES, pH 7.5 adjusted at 
RT]). 
pH Profile of AAC(6’)-APH(2”)(NHis) and AAC(3)-IV(N His) Purified from pET28a. 
The pH profile of AAC(6’)-APH(2”)(NHis) and AAC(3)-IV(NHis) purified from pET28a 
were determined for each aminoglycoside substrate (200 µL reaction volume) by 
monitoring CoA-SH, released due to acylation, reacting with 4,4’-dithiodipyridine 
which gives an increase in absorbance at 324 nm (ε324 = 19 800 M-1cm-1)[2] due to the 
formation of 4-thiopyridone, using acetyl-CoA (40 µM), DTDP (2 mM), and aminogly-
coside (20 µM) in the various buffers (50 mM). A pH range from 4.5 to 9.0 using 0.3 
increments was used to determine the optimum pH of the AACs activity with individu-
al sugars. Citrate-phosphate buffer (50 mM) was used for pHs 4.5 to 5.4, MES (50 
mM) was used for pHs 5.7 to 6.6, HEPES (50 mM) for pHs 6.9 to 7.8, and Tris (50 
mM) for pHs 8.1 to 9.0. Data were recorded every 30 s for 15 to 30 min. The rate of 
each reaction was determined using the initial slope (in the first 2.5 min), and plotted 
versus the pH (Figure S5). Plots generally indicated one optimum pH or a small 
range of pHs. 
Determination of CoA Derivatives Substrate Specific ity for AAC(6’)-APH(2”)-
(NHis) and AAC(3)-IV(NHis) from pET28a. To determine which CoA derivatives are 
substrates for AAC(6’)-APH(2”)(NHis) and AAC(3)-IV(NHis) from pET28a, the acyla-
tion of the aminogylcosides were monitored using the same spectrophotometric as-
say as above. Reaction volumes of 200 µL contained buffer (50 mM) [MES pH 6.6 for 
the AAC(6’)-APH(2”) enzyme for all aminoglycosides, MES pH 6.6 for the AAC(3)-IV 
enzyme for paromomycin and tobramycin, and MES pH 5.7 for AAC(3)-IV enzymes 
for gentamicin, sisomicin, and neomycin B], DTDP (2 mM), CoA derivatives (40 µM), 
and aminogylcoside (20 µM). The reactions were initiated using 5.9 µg of protein. Sol-
utions were pre-incubated at 37 °C for 5 min prior to addition of enzyme. The enzy-
matic reactions were monitored by taking readings every 30 s for 30 min (Figures S6-
S10). 
Determination of Kinetic Paramaters. The kinetic parameters for each enzyme 
were determined in reactions (200 µL) containing 0-80 µM of CoA derivatives (0, 1, 2, 
3, 4, 5, 6, 10, 20, 30, 40, 80 µM) (higher concentrations, up to 1 mM, were used in 
cases that revealed a Km higher than 80 µM), aminoglycoside (100 µM), DTDP (2 mM), 
and enzyme (0.25 µM) at the optimum pH for individual aminoglycosides as deter-
mined by the pH profile (i.e. the pH giving the fastest rate). Reactions were initiated 
by the addition of the CoA derivatives and were carried out in triplicate. The kinetic 
parameters, Km and kcat were determined using Lineweaver-Burke plots (Figures 
S11-S13). The determination of kinetic parameters using ThioGlo-1 (TG1) was done 
identically, only using TG1 (100 µM) in place of DTDP. 
TLC Time Course.  Reactions (100 µL) were carried out at 37 °C (AAC(6 ’)-APH(2”)) 
or at RT (AAC(3)-IV) in MES (50 mM, pH 6.6 adjusted at RT) (neomycin B) or at RT 
in MES (50 mM, pH 5.7 adjusted at RT) (gentamicin) in the presence of CoA deriva-
tive (200 µM), aminoglycoside (150 µM), and AAC (5-6 µM). Aliquots (~5 µL) were 
loaded on a TLC plate (EMD, Silica gel F254 250 µm tickness) after 0, 10, 30, 60, 
120, 300 min, and overnight incubation. The eluent systems utilized were MeOH/ 
NH4OH 3:2 (neomycin B) and 6:1/MeOH:NH4OH (gentamicin). Visualization was 
achieved by using a cerium-molybdate stain (5 g CAN, 120 g ammonium molybdate, 
80 mL H2SO4, 720 mL H2O). The Rf values observed were 0.23 for neomycin B; 0.43 
for 6’-N-acetyl-neomycin B; 0.47 for 6’-N-n-propionyl-neomycin B; 0.31 for 3-N-acetyl-
neomycin B; 0.42 for 3-N-n-propionyl-neomycin B; 0.10 for gentamicin; 0.20 for 3-N-
acetyl-gentamicin; 0.27 for 3-N-n-propionyl-gentamicin Starting materials and by-
product were visualized by TLC to determine their Rf values using the appropriate 
eluent systems (Figure S14). 
TLC time course for double acetylation of neomycin B. Reactions (100 µL) were 
carried out at 37 °C (for AAC(6’)-APH(2”)) or at RT  (for AAC(3)-IV) in MES (50 mM, 
pH 5.7 adjusted at RT) in the presence of acetyl-CoA (600 µM), aminoglycoside (150 
µM), and AAC (6 µM) for 1 h. The second AAC was added to the mixture and the 
reaction was incubated for an additional 1 h. Aliquots (5 µL) of each reaction were 
loaded onto a TLC plate (EMD, Silica gel F254 250 µm tickness). The eluent systems 
utilized were MeOH/NH4OH 3:2 and visualization was achieved by using a cerium-
molybdate stain (5 g CAN, 120 g ammonium molybdate, 80 mL H2SO4, 720 mL H2O). 
The Rf values observed were 0.46 for 6’,3-N-diacetyl-neomycin B. 
BioTLC. Reactions (10-20 µL) were inspired by the work of Ostash et al.[3] and were 
carried out in MES (50 mM, pH 6.6 adjusted at RT) for AAC(6’)-APH(2”) (0.7 nmol) or 
MES (50 mM, pH 5.7 adjusted at RT) for AAC(3)-IV (0.5 nmol) in the presence of 
CoA derivative (40-80 nmol), aminoglycoside (neomycin B, gentamicin) (30-60 nmol). 
After completion of the reaction (monitored by TLC), an equal volume of MeOH was 
added to precipitate the protein. The solutions were centrifuged (14 000 rpm, 10 min, 
RT) to pellet the protein. The entire reaction mixture was loaded onto a TLC plate 
and ran in the aforementioned eluent systems. A small amount of the reaction was 
stained with a cerium-molybdate stain prior to loading on the BioTLC to check for 
reaction completion. Bacillus subtilis was grown in LB (no antibiotic) at 30 °C for a 24 
h period. The bacterial culture (100 µL) was added to soft agar (0.75%) LB (10 mL) at 
37 °C and poured over the TLC plate in a sterile pe tri dish. The B. subtilis overlay 
was grown until clear zones of inhibited growth were observed (10 h – overnight) at 
30 °C. The R f values of the starting materials and products on the stained TLCs cor-




Figure S1.  Coomassie blue-stained 15% Tris-HCl SDS-PAGE gel showing the purified 
AAC(6’)-APH(2”)(no tag) (Int-pET19b-pps) (56992 Da, lane 1), AAC(6’)-APH(2”)(NHis) (Int-
pET19b-pps) (60897 Da, lane 2), AAC(6’)-APH(2”)(NHis) (pET28a) (59155 Da, lane 3), 
AAC(6’)-APH(2”)(CHis) (pET22b) (57678 Da, lane 4), AAC(3)-IV(no tag) (Int-pET19b-pps) 
(27906 Da, lane 5), AAC(3)-IV(NHis) (Int-pET19b-pps) (31882 Da, lane 6), and AAC(3)-




Figure S2. TLC time courses using acetyl-CoA or n-propionyl-CoA of the A. AAC(6’)-
APH(2”) reactions with neomycin B showing the formation of 6’-N-acetyl-neomycin B and 6’-
N-n-propionyl-neomycin B, B. AAC(3)-IV reaction with neomycin B showing the formation of 
3-N-acetyl-neomycin B and 3-N-n-propionyl-neomycin B, and C. AAC(3)-IV reaction with 
gentamicin showing the formation of 3-N-acetyl-gentamicin and 3-N-n-propionyl-gentamicin. 
D. Control TLC showing that without an AAC enzyme the substrate remains unchanged, 




Figure S3.  FPLC traces observed at 280 nm for A AAC(6’)-APH(2”)(CHis) (pET22b), B AAC(6’)-APH(2”)(NHis) (Int-pET19b-pps), C AAC(6’)-
APH(2”)(no tag) (Int-pET19b-pps), and D AAC(6’)-APH(2”)(NHis) (pET28a). 
 
 




Figure S5.  Representative pH profiles for A kanamycin A with AAC(6’)-APH(2”)(NHis) 
(pET28a), B sisomicin with AAC(6’)-APH(2”)(NHis) (pET28a), C sisomicin with AAC(3)-
IV(NHis) (pET28a), and D paromomycin with AAC(3)-IV(NHis) (pET28a). 
 
Figure S6.  Representative spectrophotometric assay plots of A. “good” substrates with ami-
kacin and AAC(6’)-APH(2”)(NHis) (pET28a), B. “moderate and poor” substrates with amika-
cin and AAC(6’)-APH(2”)(NHis) (pET28a), C. “good” substrates with kanamycin A and 
AAC(6’)-APH(2”)(NHis) (pET28a), D. “moderate and poor” substrates with kanamycin A and 
AAC(6’)-APH(2”)(NHis) (pET28a), E. “good” substrates with paromomycin and AAC(3)-
IV(NHis) (pET28a), and F. “poor” substrates with paromomycin and AAC(3)-IV(NHis) 
(pET28a). 
 
Figure S7.  Representative spectrophotometric assay plots of A. “good” substrates with 
gentamicin and AAC(6’)-APH(2”)(NHis) (pET28a), B. “moderate and poor” substrates with 
gentamicin and AAC(6’)-APH(2”)(NHis) (pET28a), C. “good” substrates with gentamicin and 
AAC(3)-IV(NHis) (pET28a), D. “poor” substrates with gentamicin and AAC(3)-IV(NHis) 
(pET28a), and E. “poor” substrates with gentamicin and AAC(3)-IV(NHis) (pET28a). 
 
 
Figure S8.  Representative spectrophotometric assay plots of A. “good” substrates with 
neomycin B and AAC(6’)-APH(2”)(NHis) (pET28a), B. “moderate and poor” substrates with 
neomycin and AAC(6’)-APH(2”)(NHis) (pET28a), C. “good” substrates with neomycin B and 
AAC(3)-IV(NHis) (pET28a), D. “moderate” substrates with neomycin B and AAC(3)-IV(NHis) 
(pET28a), E. “poor” substrates with neomycin B and AAC(3)-IV(NHis) (pET28a), and F. 
“poor” substrates with neomycin B and AAC(3)-IV(NHis) (pET28a). 
 
Figure S9.  Representative spectrophotometric assay plots of A. “good” substrates with 
sisomicin and AAC(6’)-APH(2”)(NHis) (pET28a), B. “moderate and poor” substrates with 
sisomicin and AAC(6’)-APH(2”)(NHis) (pET28a), C. “good” substrates with sisomicin and 
AAC(3)-IV(NHis) (pET28a), D. “poor” substrates with sisomicin and AAC(3)-IV(NHis) 
(pET28a), and D. “poor” substrates with sisomicin and AAC(3)-IV(NHis) (pET28a). 
 
Figure S10.  Representative spectrophotometric assay plots of A. “good” substrates with 
tobramycin and AAC(6’)-APH(2”)(NHis) (pET28a), B. “moderate and poor” substrates with 
tobramycin and AAC(6’)-APH(2”)(NHis) (pET28a), C. “good” substrates with tobramycin and 
AAC(3)-IV(NHis) (pET28a), D. “poor” substrates with tobramycin and AAC(3)-IV(NHis) 
(pET28a), and E. “poor” substrates with tobramycin and AAC(3)-IV(NHis) (pET28a). 
 
Figure S11.  Example kinetic initial rates of A. kanamycin A with AAC(6’)-APH(2”)(CHis) 
(pET22b) and acetyl-CoA, B. kanamycin A with AAC(6’)-APH(2”)(CHis) (pET22b) and n-
propionyl-CoA, C. kanamycin A with AAC(6’)-APH(2”)(NHis) (Int-pET19b-pps) and acetyl-
CoA, D. kanamycin A with AAC(6’)-APH(2”)(NHis) (Int-pET19b-pps) and n-propionyl-CoA, E. 
kanamycin A with AAC(6’)-APH(2”)(NHis) (pET28a) and acetyl-CoA, F. kanamycin A with 
AAC(6’)-APH(2”)(NHis) (pET28a) and n-propionyl-CoA, G. kanamycin A with AAC(6’)-
APH(2”)(no tag) (Int-pET19b-pps) and acetyl-CoA, H. kanamycin A with AAC(6’)-APH(2”)(no 
tag) (Int-pET19b-pps) and n-propionyl-CoA, I. neomycin B with AAC(6’)-APH(2”)(CHis) 
(pET22b) and acetyl-CoA, and J. neomycin B with AAC(6’)-APH(2”)(CHis) (pET22b) and n-
propionyl-CoA. 
 
Figure S12.  Example kinetic initial rates of A. amikacin with AAC(6’)-APH(2”)(CHis) 
(pET22b) and acetyl-CoA, B. amikacin with AAC(6’)-APH(2”)(CHis) (pET22b) and n-propi-
onyl-CoA, C. amikacin with AAC(6’)-APH(2”)(CHis) (pET22b) and malonyl-CoA, D. genta-
mycin with AAC(6’)-APH(2”)(CHis) (pET22b) and acetyl-CoA, E. gentamicin with AAC(6’)-
APH(2”)(CHis) (pET22b) and n-propionyl-CoA, F. gentamicin with AAC(6’)-APH(2”)(CHis) 
(pET22b) and malonyl-CoA, G. sisomicin with AAC(6’)-APH(2”)(CHis) (pET22b) and acetyl-
CoA, H. sisomicin with AAC(6’)-APH(2”)(CHis) (pET22b) and n-propionyl-CoA, I. tobramycin 
with AAC(6’)-APH(2”)(CHis) (pET22b) and acetyl-CoA, and J. tobramycin with AAC(6’)-
APH(2”)(CHis) (pET22b) and n-propionyl-CoA. 
 
Figure S13.  Example kinetic initial rates of A. gentamicin with AAC(3)-IV(NHis) (Int-pET19b-
pps) and acetyl-CoA, B. gentamicin with AAC(3)-IV(NHis) (Int-pET19b-pps) and n-propionyl-
CoA, C. paromomycin with AAC(3)-IV(NHis) (Int-pET19b-pps) and acetyl-CoA, D. 
paromomycin with AAC(3)-IV(NHis) (Int-pET19b-pps) and n-propionyl-CoA, E. tobramycin 
with AAC(3)-IV(NHis) (Int-pET19b-pps) and acetyl-CoA, F. tobramycin with AAC(3)-IV(NHis) 
(Int-pET19b-pps) and n-propionyl-CoA, G. neomycin B with AAC(3)-IV(NHis) (Int-pET19b-
pps) and acetyl-CoA, H. neomycin B with AAC(3)-IV(NHis) (Int-pET19b-pps) and n-propionyl-
CoA, I. sisomicin with AAC(3)-IV(NHis) (Int-pET19b-pps) and acetyl-CoA, and J. sisomicin 
with AAC(3)-IV(NHis) (Int-pET19b-pps) and n-propionyl-CoA. 
 
 
Figure S14. TLC visualization of AAC reaction starting materials and byproduct A. neomycin 
B (Rf = 0.23) (lane 1), acetyl-CoA (Rf = 0.91) (lane 2), and CoASH (Rf = 0.71) (lane 3) using 
a solvent system of 3:2/MeOH:NH4OH, and B. gentamicin (Rf = 0.28) (lane 4), acetyl-CoA (Rf 
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